Investment Analysts’ Weekly Ratings Changes for Century Therapeutics (IPSC)

Century Therapeutics (NASDAQ: IPSC) recently received a number of ratings updates from brokerages and research firms:

• 4/3/2025 – Century Therapeutics had its price target lowered by analysts at HC Wainwright from $5.00 to $2.00. They now have a “buy” rating on the stock.
• 3/28/2025 – Century Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim.
• 3/24/2025 – Century Therapeutics had its price target lowered by analysts at Chardan Capital from $11.00 to $7.00. They now have a “buy” rating on the stock.
• 3/21/2025 – Century Therapeutics had its price target lowered by analysts at Guggenheim from $12.00 to $5.00. They now have a “buy” rating on the stock.
• 3/20/2025 – Century Therapeutics had its price target lowered by analysts at Piper Sandler from $4.00 to $2.00. They now have an “overweight” rating on the stock.

Century Therapeutics Stock Performance

Century Therapeutics stock opened at $0.44 on Monday. The firm has a market cap of $37.78 million, a price-to-earnings ratio of -0.24 and a beta of 1.83. Century Therapeutics, Inc. has a 52-week low of $0.40 and a 52-week high of $4.43. The firm has a 50 day moving average price of $0.66 and a two-hundred day moving average price of $1.08.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.02. The business had revenue of $4.18 million during the quarter, compared to the consensus estimate of $0.67 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. As a group, equities research analysts predict that Century Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently added to or reduced their stakes in IPSC. Casdin Capital LLC grew its position in shares of Century Therapeutics by 61.6% during the 4th quarter. Casdin Capital LLC now owns 5,190,506 shares of the company’s stock worth $5,242,000 after buying an additional 1,978,190 shares during the period. Millennium Management LLC increased its position in Century Therapeutics by 1,041.8% in the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock valued at $1,623,000 after buying an additional 1,466,415 shares in the last quarter. Renaissance Technologies LLC raised its stake in Century Therapeutics by 146.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock worth $1,215,000 after buying an additional 714,685 shares during the period. Geode Capital Management LLC raised its stake in Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock worth $1,002,000 after buying an additional 23,413 shares during the period. Finally, State Street Corp boosted its holdings in Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after acquiring an additional 57,323 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.